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Despite continuous advances in the knowledge of breast cancer pathophysiology, this type of neoplasia remains a leading cause of cancer-related death in women, with more than 450 000 deaths every year worldwide. 1 surgery, coupled with radiation and/or chemotherapy, remains the main approach for breast cancer treatment. However, another common therapeutic option is based on the use of the estrogen receptor (eR) antagonist, tamoxifen. 2 indeed, approximately 60-70% of early-stage breast cancers overexpress the eR, making their growth dependent on estrogens. Tamoxifen blocks estrogen signaling by competitively binding the eR, thus antagonizing its proliferative and pro-survival effects.
Breast cancers can be inherently drugresistant or develop resistance after exposure to chemotherapeutic drugs, such as the anthracyline, doxorubicin. 1 Resistance can also develop in patients receiving tamoxifen. 2 Therefore, it is very important to understand how breast cancers become drug-and hormone-resistant, and whether or not their drug-resistance can be reversed. There also is a need for novel targeted therapies for breast cancer patients who develop resistance to traditional therapies.
GsK-3β is a serine/threonine kinase involved in several signal transduction cascades, including the Pi3K/Akt/mTOR, wnt/βcatenin, and MeK/eRK pathways. 3 in particular, Akt and other kinases phosphorylate GsK-3β at ser9. This phosphorylative event inactivates GsK-3β3. GsK-3β regulates cell cycle progression, differentiation, survival, embryogenesis, migration, and metabolism. However, aberrant GsK-3β activity has been linked with an increasing number of pathologies, including cancer, heart disease, immune system disorders, diabetes, atherosclerosis, and different neurological diseases. 3 Although its role in cancer remains controversial, GsK-3β has also been implicated in breast cancer development and drug resistance. 4, 5 Using eR-positive MCF-7 breast cancer cells, sokolosky and coworkers have performed a detailed analysis of the roles played by GsK-3β in causing resistance to doxorubicin or tamoxifen. 6 They found that MCF-7 cells overexpressing a kinase-dead (KD) form of GsK-3β were more resistant to doxorubicin and tamoxifen compared with MCF-7 cells overexpressing either wild-type (wT) or constitutively active (CA) GsK-3β. ectopic expression of GsK-3β(KD) also resulted in increased clonogenic activity of MCF-7 cells in comparison with either GsK-3β(wT) or GsK-3β(CA) overexpression.
Moreover, treatment of parental MCF-7 and MCF-7/GsK-3β(wT) cells with doxorubicin abrogated the phosphorylation of GsK-3β at ser9. in contrast, ser9 p-GsK-3β was still detectable in MCF-7/GsK-3β(KD) and MCF-7/ GsK-3β(CA) cells. This indicated that one of the effects of doxorubicin on MCF-7 cells was suppression of ser9 p-GsK-3β, which could then result in increased GsK-3β activity. Downregulation of ser9 p-GsK-3β levels was detected despite increased Akt activity induced in these cell types by doxorubicin. This finding documented that the control of GsK-3β activity is complex and multi-factorial in MCF-7 cells, as there may be several alternate routes of GsK-3β inactivation that are independent of Akt, 3 including downregulation of protein phosphatase activity or upregulation of other kinases (Fig. 1) .
what is even more interesting, MCF-7/ GsK-3β(KD) cells displayed an elevated sensitivity to the mTORC1 inhibitor, rapamycin, compared with MCF-7/GsK-3β(wT) or MCF-7/ GsK-3β(CA) cells, while concurrent MeK/eRK inhibition alleviated doxorubicin and tamoxifen resistance in MCF-7/GsK-3β(KD) cells (Fig. 1) . Overall, these results demonstrated that GsK-3β is a key regulatory molecule in sensitivity of breast cancer cells to chemo-, 
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Volume 13 issue 5 hormonal, and targeted therapy ( Fig. 1) . Moreover, they fit well with the conclusions of an immunohistochemical study performed on paraffin-embedded samples from 72 consecutive invasive mammary carcinomas, which documented how higher ser9 p-GsK-3β levels correlated with a worse clinical outcome in eR-positive cases. 7 GsK-3β-controlled drug resistance may be mediated by the BH3-only member of the Bcl-2 family, Mcl-1. indeed, the expression levels of this anti-apoptotic protein inversely correlated with GsK-3β activity (assessed by immunostochemical staining for p-GsK-3β) in breast cancer specimens, and active GsK-3β was found to be required for proteasome-mediated Mcl-1 degradation. 8 in conclusion, the findings by sokolosky et al. 6 unequivocally demonstrated that loss of GsK-3β kinase activity could dramatically increase the drug and hormonal resistance of breast cancer cells. However, this may confer an Achilles' heel by sensitizing cancer cells to targeted therapy with small-molecule kinase inhibitors. Although further studies are needed to determine the clinical relevance of the complex interactions between GsK-3β, mTORC1, and MeK/eRK, it could be envisaged that mTORC1 and MeK/eRK inhibitors should be able to potentiate the effects of chemoand hormonal therapy, thereby presenting an attractive treatment route for overcoming GsK-3β-mediated drug-resistance in breast cancer.
